Patients with Colorectal Cancer Have Medicine Approved by Anvisa
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.8 Articles
8 Articles
The National Agency for Health Surveillance (Anvisa) approved, on Monday (31), the registration of the medicine Fruzaqla (fruquintinib) for the treatment of metastatic colorectal cancer in adults. The product is indicated for patients who have already undergone previous treatments with chemotherapy based on fluoropyrimidine, oxaliplatin and irinotecan, in addition to anti-VEGF therapies and, when appropriate, anti-EGFR. [...]
The National Agency of Health Surveillance (Anvisa) approved, on Monday, 31, the registration of the medicine Fruzaqla (fruquintinibbe). The post Anvisa approves new medicine against cancer that increases the survival of patients appeared first on GMC Online.
Adult patients treated against metastatic colorectal cancer have the medicine Fruzaqla (fruquintinib) as an option for treatment. The National Agency for Health Surveillance (Anvisa) approved the registration of the substance on Monday (31). The product is indicated for the treatment of patients, among other situations, who have already undergone chemotherapy based on fluoropyrimidine, oxaliplatin and [...] The post Anvisa approves new medicine …
Brasilia, Aug 31 (Latin Press) Brazil's National Health Surveillance Agency (Anvisa) today approved a new drug for adult patients with metastatic colorectal cancer who received treatments for the disease. The post They approve in Brazil drug against metastatic colorectal cancer first appeared on Noticias Prensa Latina.
Tribuna Online
Adult patients treated with metastatic colorectal cancer have the medicine Fruzaqla (fruquintinib) as an option for treatment. The National Agency for Health Surveillance (Anvisa) approved the registration of the substance on Monday (31).The product is indicated for the treatment of patients, among other situations, who have already undergone chemotherapy based on fluoropyrimidine, oxaliplatin and irinotecan.Fruzquintinib is a medicine that spec…
Approved drug showed significant increase in survival in patients previously treated with chemotherapy
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
